...

TriCore's First Chief Scientific Officer


08/14/2017

Albuquerque-based TriCore Reference Laboratories has established a new executive role to focus on research, the company announced.

David Grenache, Ph.D,  who currently is a clinical professor of pathology at the University of Utah School of Medicine and medical director in the chemistry division at ARUP Laboratories in Salt Lake City, will serve as TriCore’s first chief scientific officer.

TriCore said Grenache will begin his job in September.

In his new role, Grenache will be responsible for oversight of the core lab’s strategic direction and planning, as well as contributing to the leadership of the TriCore Research Institute.  A core lab is a diagnostic facility where more complex testing is conducted, as opposed to the rapid response testing done at a TriCore’s hospital sites.  TriCore’s core lab performs 10.5 million clinical tests each year.

In addition to its core lab operations, TriCore, a not-for-profit, has 30 patient care centers throughout New Mexico.

TriCore’s executive team hailed the new appointment.

“I have been fortunate to know Dr. Grenache for many years through the American Association for Clinical Chemistry, where he has served in multiple capacities,” said Dr. Michael Crossey, TriCore’s chief medical officer. “He is widely known as a leading expert in maternal/fetal clinical chemistry issues and one of the best clinical chemists and medical educators I know.”

Khosrow Shotorbani, TriCore’s president and CEO, said New Mexico is gaining a new healthcare executive with “true international expertise,” and the company should profit as a result.

Grenache’s reearch interests are focused on reproductive biochemistry and emerging biomakers of disease.

Co-sponsored by Presbyterian Healthcare Services and University of New Mexico Health Sciences Center, TriCore currently has 1,300 employees in the state.


David Grenache, PhD

TriCore in the News

With technology developed by TGen, the test allows for rapid definitive diagnosis of Valley Fever

DxNA LLC, a molecular diagnostics
company, today announced the regulatory clearance by the U.S. Food and Drug
Administration (FDA) to market its molecular test for rapid detection of
Coccidioidomycosis (Valley Fever) using DxNA’s GeneSTAT.MDx Coccidioides
test and proprietary GeneSTAT System.

www.dxna.com,12/11/2017

American Healthcare Leader - Switching Gears

World-class cyclist Dina Hannah goes the extra mile inside and out of the office at TriCore Reference Laboratories.

American Healthcare Leader,10/02/2017

Outreach: Forge ahead or accept purchase bid

With the laboratory industry in flux—and many critical determinants of the next few years waiting on policy moves by the new administration and third-party payers—hospital outreach programs could wish for a better time to make existential decisions such as accepting an offer to be purchased.

CAP Today,08/15/2017

3 New Mexicans to Know

I had the pleasure of spending part of this morning with 350 eighth graders from Tony Hillerman Middle School, and it gave me some pleasant perspective.

These kids face the awesomely foreboding prospect of entering high school next year and all the terrifying mysteries that entails. Believe me when I tell you, their parents feel exactly the same way — excited and very, very nauseous.

Albuquerque Business First,05/25/2017

Recent Tweets

Follow us on Twitter